Budoprutug clinical trials
Also written TNT119 and VB119.
How each study uses budoprutug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the budoprutug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test budoprutug.
- Apr 2027A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)Phase 1 · Climb Bio, Inc.
- Aug 2027A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)Phase 1/2 · Climb Bio, Inc.
- Sep 2027A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)Phase 1/2 · Climb Bio, Inc.
- Oct 2027A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyPhase 2 · Climb Bio, Inc.
Studies
Open first, then newest update. How each study uses budoprutug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)RecruitingPhase 1/2Climb Bio, Inc.NCT07564596Written as Budoprutug
- A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyRecruitingPhase 2Climb Bio, Inc.NCT07096843Written as budoprutug
- A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)RecruitingPhase 1Climb Bio, Inc.NCT07011043Written as Budoprutug
- A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)RecruitingPhase 1/2Climb Bio, Inc.NCT07043946Written as Budoprutug
- A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy VolunteersCompletedEarly Phase 1Climb Bio, Inc.NCT07090655Written as Budoprutug
- Efficacy and Safety of VB119 in Subjects With Membranous NephropathyTerminatedPhase 1/2Tenet MedicinesNCT04652570Written as VB119
- Phase 1b/2a in SLE With BudoputugWithdrawnPhase 1/2Tenet MedicinesNCT06570434Written as budoprutug
- Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)TerminatedPhase 2Tenet MedicinesNCT05441826Written as VB119
Codes
What other systems call budoprutug · ClinicalTrials.gg INT016412
- UNII (FDA) E4ET672BAPBUDOPRUTUGOne source FDA
- NCI Thesaurus C203028BudoprutugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E4ET672BAP | BUDOPRUTUG | One source FDA |
| NCI Thesaurus | C203028 | Budoprutug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.